{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,8,18]],"date-time":"2026-08-18T10:24:32Z","timestamp":1787048672112,"version":"build-2736575974"},"reference-count":50,"publisher":"Informa UK Limited","issue":"1","license":[{"start":{"date-parts":[[2026,8,18]],"date-time":"2026-08-18T00:00:00Z","timestamp":1787011200000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0\/"},{"start":{"date-parts":[[2026,8,18]],"date-time":"2026-08-18T00:00:00Z","timestamp":1787011200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/doi.org\/10.1080\/policies-text-data-mining"}],"funder":[{"name":"Merck Sharp & Dohme LLC"}],"content-domain":{"domain":["www.tandfonline.com"],"crossmark-restriction":true},"short-container-title":["Journal of Medical Economics"],"published-print":{"date-parts":[[2026,12,31]]},"DOI":"10.1080\/13696998.2026.2713865","type":"journal-article","created":{"date-parts":[[2026,8,18]],"date-time":"2026-08-18T09:28:45Z","timestamp":1787045325000},"page":"2161-2176","update-policy":"https:\/\/doi.org\/10.1080\/tandf_crossmark_01","source":"Crossref","is-referenced-by-count":0,"title":["Cost-effectiveness of perioperative pembrolizumab plus enfortumab vedotin for cisplatin-ineligible or cisplatin-declining patients with muscle-invasive bladder cancer in the United States"],"prefix":"10.1080","volume":"29","author":[{"ORCID":"https:\/\/orcid.org\/0000-0002-1936-3907","authenticated-orcid":false,"given":"Daniel","family":"Hill-McManus","sequence":"first","affiliation":[{"name":"MSD (UK) Limited","place":["London, UK"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yizhen","family":"Lai","sequence":"additional","affiliation":[{"name":"Merck & Co., Inc","place":["Rahway, USA"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Arielle G.","family":"Bensimon","sequence":"additional","affiliation":[{"name":"Analysis Group, Inc","place":["Boston, USA"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Joshua","family":"Young","sequence":"additional","affiliation":[{"name":"Analysis Group, Inc","place":["Boston, USA"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Kelly","family":"Reeve","sequence":"additional","affiliation":[{"name":"MSD","place":["Zurich, Switzerland"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Anjela","family":"Tzontcheva","sequence":"additional","affiliation":[{"name":"MSD","place":["Zurich, Switzerland"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0009-0003-6819-5764","authenticated-orcid":false,"given":"Patrick","family":"Squires","sequence":"additional","affiliation":[{"name":"Merck & Co., Inc","place":["Rahway, USA"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0009-0001-7030-6780","authenticated-orcid":false,"given":"Haojie","family":"Li","sequence":"additional","affiliation":[{"name":"Merck & Co., Inc","place":["Rahway, USA"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Chethan","family":"Ramamurthy","sequence":"additional","affiliation":[{"name":"Merck & Co., Inc","place":["Rahway, USA"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Matthew","family":"Mossanen","sequence":"additional","affiliation":[{"name":"Brigham and Women\u2019s Hospital","place":["Boston, USA"]}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"301","published-online":{"date-parts":[[2026,8,18]]},"reference":[{"key":"e_1_3_5_2_1","doi-asserted-by":"publisher","DOI":"10.3233\/BLC-230062"},{"key":"e_1_3_5_3_1","unstructured":"European Association of Urology. Muscle-invasive and metastatic bladder cancer. 2026 Feb 27. Available from: https:\/\/uroweb.org\/guidelines\/muscle-invasive-and-metastatic-bladder-cancer\/chapter\/staging-and-classification-systems"},{"key":"e_1_3_5_4_1","doi-asserted-by":"publisher","DOI":"10.1016\/s1078-1439(03)00145-5"},{"key":"e_1_3_5_5_1","doi-asserted-by":"publisher","DOI":"10.1016\/S0140-6736(09)60491-8"},{"key":"e_1_3_5_6_1","doi-asserted-by":"publisher","DOI":"10.1016\/S0140-6736(16)30512-8"},{"key":"e_1_3_5_7_1","unstructured":"European Association of Urology. Guidelines: muscle-invasive and metastatic bladder cancer. 2026."},{"key":"e_1_3_5_8_1","doi-asserted-by":"publisher","DOI":"10.1093\/oncolo\/oyae160"},{"key":"e_1_3_5_9_1","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa2034442"},{"key":"e_1_3_5_10_1","doi-asserted-by":"publisher","DOI":"10.1111\/bju.12274"},{"key":"e_1_3_5_11_1","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa022148"},{"key":"e_1_3_5_12_1","doi-asserted-by":"publisher","DOI":"10.1111\/bju.16895"},{"key":"e_1_3_5_13_1","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa2511674"},{"key":"e_1_3_5_14_1","unstructured":"U.S. Food and Drug Administration. FDA approves pembrolizumab with enfortumab vedotin-ejfv for muscle invasive bladder cancer. 2025. Available from: https:\/\/www.fda.gov\/drugs\/resources-information-approved-drugs\/fda-approves-pembrolizumab-enfortumab-vedotin-ejfv-muscle-invasive-bladder-cancer"},{"key":"e_1_3_5_15_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.jval.2025.03.010"},{"key":"e_1_3_5_16_1","doi-asserted-by":"publisher","DOI":"10.1177\/17588359241295544"},{"key":"e_1_3_5_17_1","doi-asserted-by":"publisher","DOI":"10.3389\/fimmu.2024.1464092"},{"key":"e_1_3_5_18_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.ejca.2025.115621"},{"key":"e_1_3_5_19_1","unstructured":"National Institute for Health and Care Excellence. Enfortumab vedotin with pembrolizumab for untreated unresectable or metastatic urothelial cancer when platinum-based chemotherapy is suitable [TA1097]. 2025. Available from: https:\/\/www.nice.org.uk\/guidance\/ta1097"},{"key":"e_1_3_5_20_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.jval.2025.04.960"},{"key":"e_1_3_5_21_1","first-page":"841","article-title":"Peri-operative treatment patterns in real-world muscle-invasive bladder cancer patients undergoing radical cystectomy in the era of adjuvant immunotherapy","author":"Squires P","year":"2025","unstructured":"Squires P, Meng K, Hu X, et al. Peri-operative treatment patterns in real-world muscle-invasive bladder cancer patients undergoing radical cystectomy in the era of adjuvant immunotherapy. Am Soc Clin Oncol. 2025;14(2):841\u2013853.","journal-title":"Am Soc Clin Oncol"},{"key":"e_1_3_5_22_1","unstructured":"Institute for Clinical and Economic Review. ICER\u2019s reference case for economic evaluations: elements and rationale. 2025 [2026 Mar 30]. Available from: https:\/\/icer.org\/wp-content\/uploads\/2024\/02\/ICER_Reference-Case_For-Publication_102325.pdf"},{"key":"e_1_3_5_23_1","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa2312117"},{"key":"e_1_3_5_24_1","doi-asserted-by":"crossref","unstructured":"Arias E Xu J Kochanek K. United States life tables 2023. 2025.","DOI":"10.15620\/cdc\/174591"},{"key":"e_1_3_5_25_1","doi-asserted-by":"publisher","DOI":"10.1177\/0272989X16651869"},{"key":"e_1_3_5_26_1","doi-asserted-by":"publisher","DOI":"10.1177\/0272989X16670617"},{"key":"e_1_3_5_27_1","unstructured":"IQVIA Predictive Model Market Sizing (Projected) through July. Data on file. 2025."},{"key":"e_1_3_5_28_1","unstructured":"IQVIA Market Sizing (Projected) through July. Data on file. 2025."},{"key":"e_1_3_5_29_1","doi-asserted-by":"publisher","DOI":"10.1177\/17588359251357527"},{"key":"e_1_3_5_30_1","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.1997.15.11.3394"},{"key":"e_1_3_5_31_1","doi-asserted-by":"publisher","DOI":"10.3390\/cancers17071105"},{"key":"e_1_3_5_32_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.jval.2019.02.009"},{"key":"e_1_3_5_33_1","doi-asserted-by":"crossref","unstructured":"KEYNOTE-052. Data on file. 2018.","DOI":"10.1088\/1475-7516\/2018\/03\/052"},{"key":"e_1_3_5_34_1","unstructured":"Merative Micromedex RED BOOK. Available from: https:\/\/www.micromedexsolutions.com\/home\/dispatch"},{"key":"e_1_3_5_35_1","unstructured":"Centers for Medicare & Medicaid Services. Physician Fee Schedule. 2025. Available from: https:\/\/www.cms.gov\/medicare\/physician-fee-schedule\/search"},{"key":"e_1_3_5_36_1","volume-title":"HCUP National Inpatient Sample","author":"Healthcare Cost and Utilization Project","year":"2022","unstructured":"Healthcare Cost and Utilization Project. HCUP National Inpatient Sample. Rockville (MD): Agency for Healthcare Research and Quality; 2022."},{"key":"e_1_3_5_37_1","unstructured":"US Bureau of Economic Analysis. Price indexes for personal consumption expenditures by major type of product. Personal Consumption Expenditure (PCE) Price Index Health Care; 2025 Nov. Available from: https:\/\/apps.bea.gov\/iTable\/?isuri=1&reqid=19&step=4&categories=flatfiles&nipa_table_list=1#eyJhcHBpZCI6MTksInN0ZXBzIjpbMSwyLDNdLCJkYXRhIjpbWyJjYXRlZ29yaWVzIiwiU3VydmV5Il0sWyJuaXBhX3RhYmxlX2xpc3QiLCI2NCJdXX0="},{"key":"e_1_3_5_38_1","unstructured":"US Food and Drug Administration. Pembrolizumab IV FDA label 2025. Available from: https:\/\/www.accessdata.fda.gov\/drugsatfda_docs\/label\/2025\/125514s188lbl.pdf"},{"key":"e_1_3_5_39_1","unstructured":"US Food and Drug Administration. Enfortumab vedotin FDA label 2025. Available from: https:\/\/www.accessdata.fda.gov\/drugsatfda_docs\/label\/2025\/761137s032lbl.pdf"},{"key":"e_1_3_5_40_1","unstructured":"US Food and Drug Administration. Nivolumab IV FDA label 2025. Available from: https:\/\/www.accessdata.fda.gov\/drugsatfda_docs\/label\/2025\/125554s131lbl.pdf"},{"key":"e_1_3_5_41_1","unstructured":"US Food and Drug Administration. Avelumab FDA label 2025. Available from: https:\/\/www.accessdata.fda.gov\/drugsatfda_docs\/label\/2025\/761049s021lbl.pdf"},{"key":"e_1_3_5_42_1","doi-asserted-by":"publisher","DOI":"10.1001\/jamanetworkopen.2025.14427"},{"key":"e_1_3_5_43_1","unstructured":"Fang H Raut M Zhang S et al. Real-world clinical outcomes and disease management costs among high-risk non\u2013muscle-invasive bladder cancer patients treated with Bacillus Calmette-Gu\u00e9rin: a SEER-Medicare analysis. Poster presented at: academy of Managed Care Pharmacy (AMCP) Nexus; October 27-30 National Harbor MD; 2025."},{"key":"e_1_3_5_44_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.jval.2025.04.1914"},{"key":"e_1_3_5_45_1","unstructured":"Institute for Clinical and Economic Review. ICER 2019 perspectives on cost-effectiveness threshold ranges 2019. 2026 Mar 19. Available from: https:\/\/icer.org\/wp-content\/uploads\/2023\/08\/ICER_2019_Perspectives-on-Cost-Effectiveness-Threshold-Ranges.pdf"},{"key":"e_1_3_5_46_1","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa041031"},{"key":"e_1_3_5_47_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.clgc.2025.102466"},{"key":"e_1_3_5_48_1","doi-asserted-by":"publisher","DOI":"10.1177\/17588359251357519"},{"key":"e_1_3_5_49_1","doi-asserted-by":"publisher","DOI":"10.1001\/jamanetworkopen.2019.11952"},{"key":"e_1_3_5_50_1","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.2026.44.7_suppl.LBA630"},{"key":"e_1_3_5_51_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.euo.2025.10.002"}],"container-title":["Journal of Medical Economics"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.tandfonline.com\/doi\/pdf\/10.1080\/13696998.2026.2713865","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.tandfonline.com\/doi\/full-xml\/10.1080\/13696998.2026.2713865","content-type":"application\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.tandfonline.com\/doi\/pdf\/10.1080\/13696998.2026.2713865","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,8,18]],"date-time":"2026-08-18T09:28:47Z","timestamp":1787045327000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.tandfonline.com\/doi\/full\/10.1080\/13696998.2026.2713865"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,8,18]]},"references-count":50,"journal-issue":{"issue":"1","published-print":{"date-parts":[[2026,12,31]]}},"alternative-id":["10.1080\/13696998.2026.2713865"],"URL":"https:\/\/doi.org\/10.1080\/13696998.2026.2713865","relation":{},"ISSN":["1369-6998","1941-837X"],"issn-type":[{"value":"1369-6998","type":"print"},{"value":"1941-837X","type":"electronic"}],"subject":[],"published":{"date-parts":[[2026,8,18]]},"assertion":[{"value":"The publishing and review policy for this title is described in its Aims & Scope.","order":1,"name":"peerreview_statement","label":"Peer Review Statement"},{"value":"http:\/\/www.tandfonline.com\/action\/journalInformation?show=aimsScope&journalCode=ijme20","URL":"http:\/\/www.tandfonline.com\/action\/journalInformation?show=aimsScope&journalCode=ijme20","order":2,"name":"aims_and_scope_url","label":"Aim & Scope"},{"value":"2026-06-09","order":0,"name":"received","label":"Received","group":{"name":"publication_history","label":"Publication History"}},{"value":"2026-07-30","order":1,"name":"revised","label":"Revised","group":{"name":"publication_history","label":"Publication History"}},{"value":"2026-07-31","order":2,"name":"accepted","label":"Accepted","group":{"name":"publication_history","label":"Publication History"}},{"value":"2026-08-18","order":3,"name":"published","label":"Published","group":{"name":"publication_history","label":"Publication History"}}]}}